Wednesday, November 14, 2012 Tuesday, November 13, 2012- Merck ditches work on diabetes drugat bizjournals.com (Tue, Nov 13)
- A Brief Bounce for This Biotechat Motley Fool (Tue, Nov 13)
- Verastem loss widens on R&D costsat bizjournals.com (Tue, Nov 13)
- Value Investing: Two Sectors You Must Knowat Minyanville (Tue, Nov 13)
- Areas That VIVUS Investors Must Watchat Motley Fool (Tue, Nov 13)
- Merck ends development of Januvia-Lipitor comboAP (Tue, Nov 13)
- GSK gets positive results on HIV drugat bizjournals.com (Tue, Nov 13)
- 2 Generics of Pfizer's Revatio OK'dat Motley Fool (Tue, Nov 13)
- Are We Innovating or Stagnating?at Motley Fool (Tue, Nov 13)
- AMA Wants To Stop Pharma Pay-To-Delay Tactic On Genericsat Forbes (Tue, Nov 13)
- Merck's Snoozer of a Drugat Motley Fool (Tue, Nov 13)
- Glaxo-Pfizer HIV Drug Helps Hard-to-Treat Patientsat Bloomberg (Tue, Nov 13)
- EU Nod for Novartis' VotubiaZacks (Tue, Nov 13)
- Buyout or Burnout for Amarin?at Motley Fool (Tue, Nov 13)
- Housing Is the Election's Big Winner: MillsBreakout (Tue, Nov 13)
- Worried About The Fiscal Cliff? Buy Pharmaat Seeking Alpha (Tue, Nov 13)
- Generic competition grows for Pfizer's RevatioAP (Tue, Nov 13)
- MDVN's Xtandi Off to a Strong StartZacks (Tue, Nov 13)
- 5 Key Dow Stock Insights to Watch Nowat Wall St. Cheat Sheet (Tue, Nov 13)
- Local pipefitters pension fund wins $68M class-action settlement against Pfizerat bizjournals.com (Tue, Nov 13)
- Fiscal Cliffs And Why Politicians Make Lousy Accountantsat Seeking Alpha (Tue, Nov 13)
Monday, November 12, 2012Add PFE News to My Yahoo!   | |
|
0.12%